SAN FRANCISCO--(BUSINESS WIRE)--
Invitae
Corporation (NYSE:
NVTA), a genetic information company, and its collaborators
announced the publication of new data describing the clinical
actionability of multi-gene testing for hereditary breast and ovarian
cancer (HBOC) risk in JAMA
Oncology. The study was a collaboration among Massachusetts
General Hospital, Harvard
Medical School, Stanford
University, Beth
Israel Deaconess Medical Center and Invitae.
In this paper, more than 1,000 patients were tested with multi-gene
panels, and the clinical actions that would be considered were reviewed
for all 63 patients testing positive for cancer genes other than BRCA1
or BRCA2. For more than half of these patients, the genetic test would
suggest a change in care over and above any recommendations based on the
patient’s personal and family history alone. For these patients’ family
members, testing would be warranted, as over 70% would have a change in
care considered if also found to be mutation positive.
“Multi-gene panel testing for hereditary cancer risk is an important new
development in clinical oncology and in clinical genetics practice,”
said Leif
W. Ellisen, MD, PhD, program director of breast medical oncology at Massachusetts
General Hospital, professor of medicine at Harvard
Medical School and senior author of the paper. “Our study examined a
large, clinically representative population and showed that positive
panel test results will often warrant consideration of a change in
management for the patient under current medical guidelines, certainly
more often than is true for BRCA1 and BRCA2 testing alone.”
The study authors followed the most recent recommendations from the National
Comprehensive Cancer Network (NCCN) and other applicable consensus
guidelines to determine patient care recommendations. All patients were
prospectively accrued and all met appropriate criteria for HBOC
evaluation. In the vast majority of positive cases (92%), the patients
and/or their family members’ cancers were consistent with the
scientifically well-established effects of the gene they carried,
indicating that these panel test results are clinically relevant and not
incidental findings.
“Expanding access to comprehensive genetic information can significantly
improve care and outcomes,” said Dr. Robert Nussbaum, chief medical
officer at Invitae. “I expect that payers, patients, and clinicians will
recognize that this study, as well as the data
recently published in The
Journal of Molecular Diagnostics, provide additional evidence
that genetic testing is an important component of healthcare when
carried out in accordance with responsible, guidelines-based medical
practice.”
About Invitae
Invitae’s (NYSE: NVTA) mission is to bring comprehensive genetic
information into mainstream medical practice to improve the quality of
healthcare for billions of people. Invitae’s goal is to aggregate most
of the world’s genetic tests into a single service with higher quality,
faster turnaround time and lower price than many single-gene tests
today. The company currently provides a single diagnostic service
comprising more than 200 genes for a variety of genetic disorders
associated with oncology, cardiology, neurology, pediatrics, hematology,
and other disease areas.
For more information, visit our website at ir.invitae.com
and follow us on Twitter: @invitae
and @invitaeIR.
Safe Harbor Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the company’s belief that multi-gene
panel testing is an important new development in clinical oncology and
in clinical genetics; that positive panel test results will often
warrant consideration of a change in management for the patient as
compared to BRCA1 or BRCA2 results; and the ability of comprehensive
genetic information to significantly improve care and outcomes for
people around the world. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited
to: the ability of clinical trial results to affect treatment decisions;
the company’s history of losses; the company’s need to scale its
infrastructure in advance of demand for its tests and to increase demand
for its tests; the company’s ability to generate substantial demand for
its tests; the company’s ability to develop and commercialize new tests
and expand into new markets; the risk that the company may not obtain or
maintain sufficient levels of reimbursement for its tests; risks
associated with the company’s ability to use rapidly changing genetic
data to interpret test results accurately and consistently; the
company’s ability to compete; laws and regulations applicable to the
company’s business, including potential regulation by the Food and Drug
Administration; and the other risks set forth in the company’s filings
with the Securities and Exchange Commission, including the risks set
forth in the company’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2015. These forward-looking statements speak only as of
the date hereof, and Invitae Corporation disclaims any obligation to
update these forward-looking statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the property of
their respective owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150813005216/en/
Source: Invitae Corporation